drugset
drugset / Trial / NCT03862846

A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy

NCT03862846 ↗

Phase 1 Terminated 23 enrolled Reneo Pharma Ltd
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess REN001 safety in subjects with primary mitochondrial myopathy

Timeline

Start
2019-05-10
Primary completion
2020-04-23
Completion
2020-04-23

Outcome

Outcome not reported

Stopped: “COVID-19 Pandemic sufficient data gathered to achieve the study objective”

Drugs

EvaluationDrugModalityDoseRoute
Subject Mavodelpar Small molecule — —

Indications

pure mitochondrial myopathy